country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

158 Results for "

conditioned gaping

" in MedChemExpress (MCE) Product Catalog:

Products (158)

Sort by :

Categories

By Targets

Products

Setmelanotide

8 Publications Verification

Cat. No.: HY-19870

CAS No.: 920014-72-8

Synonyms: RM-493; BIM-22493; IRC-022493

Target:

Melanocortin Receptor Calmodulin AMPK

Setmelanotide (RM-493) is a blood-brain barrier-permeable, selective MC4R agonist with a K_i value of 2.1 nM for hMC4R. Setmelanotide activates the CaMKK2/AMPK signaling pathway. Setmelanotide mediates body weight homeostasis, feeding regulation and energy expenditure modulation; it reduces food intake, induces weight loss, decreases obesity severity, increases daytime activity and energy expenditure, lowers levels of leptin, triglycerides, fasting insulin and diastolic blood pressure, improves insulin sensitivity, glucose tolerance and fatty liver condition, and reverses respiratory depression. Setmelanotide is applicable to research related to obesity, hyperinsulinemia, fatty liver and respiratory depression .

Compare

Please select quantity

August 31

Get Quote

View All Sizes

Setmelanotide monoacetate

8 Publications Verification

Cat. No.: HY-19870C

CAS No.: 2759937-80-7

Synonyms: RM-493 monoacetate; BIM-22493 monoacetate; IRC-022493 monoacetate

Target:

Melanocortin Receptor Calmodulin AMPK

Research Areas:

Cardiovascular Disease Metabolic Disease Inflammation/Immunology

Setmelanotide monoacetate (RM-493 monoacetate) is a blood-brain barrier-permeable, selective MC4R agonist with a K_i value of 2.1 nM for hMC4R. Setmelanotide monoacetate activates the CaMKK2/AMPK signaling pathway. Setmelanotide monoacetate mediates body weight homeostasis, feeding regulation and energy expenditure modulation; it reduces food intake, induces weight loss, decreases obesity severity, increases daytime activity and energy expenditure, lowers levels of leptin, triglycerides, fasting insulin and diastolic blood pressure, improves insulin sensitivity, glucose tolerance and fatty liver condition, and reverses respiratory depression. Setmelanotide monoacetate is applicable to research related to obesity, hyperinsulinemia, fatty liver and respiratory depression .

Compare